SCHEMBL73269

SCHEMBL73269

FC(F)(F)c1c[c]ccn1

nearest known ligand 0.35

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 2/20 0.35
LOX P28300 1/20 0.34
TRPV4 Q9HBA0 1/20 0.32
CA2 P00918 1/20 0.31
CHKA P35790 1/20 0.31
NOTUM Q6P988 1/20 0.30
IDO1 P14902 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17103334 0.82
SCHEMBL1727241 0.82
SCHEMBL603085 0.82
SCHEMBL129952 0.80 NR1H2 (0.31)
SCHEMBL17103295 0.79
SCHEMBL14783827 0.79
SCHEMBL1063869 0.76
SCHEMBL129482 0.73 SMN1; SMN2 (0.31)
SCHEMBL10844864 0.73
SCHEMBL28242951 0.70 TRPV4 (0.42) TRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 932 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4396181-A1 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE P2X7 ANTAGONISTS Breye Therapeutics ApS (DK) 2024-07-10 EP claimed
CN-118265702-A Microbiocidal isonicotinamide derivatives 先正达农作物保护股份公司 2024-06-28 CN claimed
CN-117986271-A Cell cycle regulator, and pharmaceutical preparation and application thereof 贵州大学 2024-05-07 CN claimed
CN-117881675-A 2, 4-dihydro-3H-1, 2, 4-triazol-3-one P2X7 antagonists 布雷耶疗法有限公司 2024-04-12 CN claimed
US-20240034737-A1 Heterocyclic Derivatives as P2X7 Receptor Antagonists BREYE THERAPEUTICS APS (DK) 2024-02-01 US claimed
CN-117157291-A Heterocyclic derivatives as P2X7 receptor antagonists 布雷耶疗法有限公司 2023-12-01 CN claimed
WO-2023227734-A1 FLAVIVIRUS INHIBITORS IRBM S.P.A. (IT) 2023-11-30 WO claimed
EP-4262975-A1 HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS Breye Therapeutics ApS (DK) 2023-10-25 EP claimed
US-11759455-B2 Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2023-09-19 US claimed
EP-3523311-B1 SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-06-07 EP claimed
US-20010011064-A1 Herbicidal 3,5-difluoropyridines AMERICAN CYANAMID COMPANY (US) 2001-08-02 US claimed
US-5972842-A SUBSTITUTED OR UNSUBSTITUTED 2?-YL THIENYL CONTAINING CYANOPYRIDINES USED AS WEED CONTROLLER AMERICAN CYANAMID COMPANY (US) 1999-10-26 US claimed
EP-0902026-A1 Herbicidal 2-azinyl-6-aryloxypyr (mi) dines American Cyanamid Company (US) 1999-03-17 EP claimed
EP-0887343-A1 Herbicidal 3,5-difluoropyridines American Cyanamid Company (US) 1998-12-30 EP claimed
US-5849758-A Herbicidal 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines AMERICAN CYANAMID COMPANY (US) 1998-12-15 US claimed
EP-0859772-A1 HERBICIDAL SUBSTITUTED PYRIDINE COMPOUNDS AMERICAN CYANAMID COMPANY (US) 1998-08-26 EP claimed
EP-0823431-A1 Herbicidal 2,6-disubstituted pyridines and 2,4-disubstituted pyrimidines American Cyanamid Company (US) 1998-02-11 EP claimed
WO-1998004550-A1 HERBICIDAL SUBSTITUTED PYRIDINE COMPOUNDS AMERICAN CYANAMID COMPANY (US) 1998-02-05 WO claimed
EP-0820996-A1 Herbicidal cyanopyridines American Cyanamid Company (US) 1998-01-28 EP claimed
EP-0723960-A1 Herbicidal 2,6-disubstituted pyridines and 2,4-disubstituted pyrimidines American Cyanamid Company (US) 1996-07-31 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240034737-A1 Heterocyclic Derivatives as P2X7 Receptor Antagonists P2RX7, P2RX3, P2RX1 LOXL2 2481/4885LOX 2145/4885TRPV4 44/4885
US-20010011064-A1 Herbicidal 3,5-difluoropyridines DDT, CYP1B1, NQO2 LOXL2 3187/4885LOX 2043/4885TRPV4 2595/4885
US-11759455-B2 Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators GRIN2B, GRIN2A, GRIN2C LOXL2 2243/4885LOX 1648/4885TRPV4 591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.